We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Stand clear

5 January 2004 By Robert Cyran

The remaining divisions in the Italian conglomerate are worth only a fraction of the medical business. While the move makes strategic sense, investors should stay clear.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)